Advertisement

BMC Gastroenterology

, 19:86 | Cite as

The association of hepatitis c virus infection status with serum glucose levels

  • Yinping Li
  • Xiaomei Wang
  • Ge Yu
  • Haibo Sun
  • Juan Lv
  • Xiumei Chi
  • Ruihong Wu
  • Xiuzhu Gao
  • Junqi NiuEmail author
Open Access
Research article
Part of the following topical collections:
  1. Hepatobiliary and pancreatic disorders

Abstract

Background

Hepatitis C virus (HCV) infection is commonly associated with a disturbance of glucose metabolism. However, there have been conflicting reports on whether the clearance of the HCV may be followed by changes of serum blood glucose and insulin resistance. The aim of the present study was to evaluate the impact of HCV and antiviral treatment on serum glucose levels and other glucose metabolism parameters.

Methods

A retrospective analysis of 306 HCV-infected patients was performed. Fasting serum blood glucose (FBG) levels in these patients were compared with that of 325 healthy individuals. Serum parameters of glucose metabolism were measured in 183 patients with chronic hepatitis C at baseline, at the end of interferon α-2b plus ribavirin treatment, and at 24 weeks post-treatment.

Results

Patients with HCV infection had significantly higher FBG level than healthy controls (5.57 ± 0.74 vs. 5.11 ± 0.83 mmol/l, P < 0.001). After antiviral treatment, we found a significant reduction in FBG levels regardless of the outcome of treatment. However, after stopping treatment the serum FBG levels were significantly elevated in the sustained virological response (SVR) and non-responder groups, and maintained high level until week 24 post-treatment. In both groups, the levels of serum FBG after 24 weeks post-treatment were still lower than pre-treatment levels. In sustained responders, fasting insulin (P = 0.007), C-peptide (P < 0.001) and HOMA-IR (P < 0.001) significantly decreased, and the insulin sensitivity index (ISI) increased (P < 0.001) at the end of the treatment comparing with pre-treatment levels, while no significant difference was observed in non-responder group. HOMA-β values were increased in both groups at the end of treatment (both P < 0.001).

Conclusion

The total serum FBG level in HCV infected patients was higher than that in healthy controls. Clearance of HCV was associated with reduced glucose and improved insulin resistance.

Keywords

Chronic hepatitis C Antiviral treatment Fasting blood glucose Sustained virological response 

Abbreviations

ALP

Alkaline phosphatase

ALT

Alanine transaminase

AST

Aspartate transaminase

BMI

Body mass index

CHC

Chronic hepatitis C

FBG

Fasting blood glucose

FCP

Fasting C peptide

FINS

fasting insulin levels

GGT

Gamma- glutamyltransferase

HCV

Hepatitis C virus

HOMA-IR

Homeostasis model assessment of insulin resistance

HOMA-β

Homeostasis model assessment- β

ISI

Insulin sensitivity index

SVR

Sustained virological response

Background

Hepatitis C virus (HCV) infects over 170 million individuals worldwide, and is an important cause of liver cirrhosis and hepatocellular carcinoma [1]. Currently, the therapy agents mainly consist of direct-acting agents such as protease, polymerase, and polymerase accessory protein inhibitors, while the interferon (IFN) and ribavirin combination therapy still plays an important role, especially in some developing countries [2].

Although HCV is a hepatotropic virus, it has also been identified in extrahepatic tissues. Numerous extrahepatic manifestations have been reported to be related to HCV infection, including mixed cryoglobulinemia, thyroiditis, a high prevalence of autoantibodies and metabolic disorders [3, 4]. Recently, much attention focuses on the association between HCV infection and the glucose intolerance [5, 6, 7]. It was believed that HCV infection could induce insulin resistance (IR). Some studies showed that the prevalence of IR ranged from 30 to 70% in HCV-infected patients regardless of the severities of liver disease, while HCV eradication could induce a decreased risk of insulin resistance [8, 9, 10, 11]. However, other studies reported that there was no association between HCV clearance and metabolic syndrome [12].

In this study, we aimed to investigate the association of HCV infection with serum glucose levels, and the impact of antiviral treatment on glucose metabolism.

Methods

Subjects

A total of 631 Chinese Han subjects were enrolled in this study, including 306 chronic hepatitis C (CHC) patients and 325 healthy controls. All subjects were originally included in a previous epidemiological investigation of HCV infection carried out by the First Hospital of Jilin University in Fuyu county of Jilin Province from 2012 to 2014. Chronic HCV infection was defined as anti-HCV positive and detectable serum HCV RNA for more than 6 months. Patients with concomitant human immunodeficiency virus, co-infection of hepatitis B virus, liver cirrhosis or diabetes mellitus were excluded. Patients who were currently receiving or recently received anti-viral treatment were also excluded. The healthy controls satisfied the following criterion: (a) body mass index (BMI) < 30 kg/m2; (b) anti-HCV was negative; (c) fasting glucose < 6.10 mmol/l. The healthy controls were also matched to CHC by age, sex and body mass index (BMI). Subjects with any liver disease or diabetes history were excluded. Baseline data including age, gender, body mass index (BMI), serum fasting blooding glucose (FBG), aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) were collected. BMI was calculated as weight in kilograms divided by height in square meters.

From the 306 CHC patients, 183 patients were selected for treatment after screening for medical and mental health-related contraindications, and were offered recombinant interferon α-2b (500,000 IU, 3 times/week, Beijing Kavin Technology Share-holding Co, Ltd. China) subcutaneously, and oral ribavirin (15 mg/kg/day) over 48 weeks (for genotype 1 and 2). This antiviral combination was selected to be studied for economic reasons. Patients were monitored until 24 weeks after the end of the treatment. All of the 183 treated patients were compliant with medications taking at least 80% of the dose and in 80% of the time, and the results of this group were analyzed.

The 183 treated patients were divided into two groups according to their virological response. Sustained virological response (SVR) was defined as an undetectable HCV RNA during at least six months after completion of therapy.

The study protocol was approved by the ethics committee of the First Hospital of Jilin University. Written informed consent for all testing was obtained prior to enrollment.

Laboratory investigations

Blood samples were obtained in the morning after more than 8 h fasting, and measured in the Clinical Laboratory of the First Hospital of Jilin University. The tests for biochemistry, liver function, renal function, blood glucose, fasting insulin and C peptide were performed using a Synchron LX®20 autoanalyser (Beckman Coulter, Brea, CA, USA). HCV RNA was determined by quantitative real-time polymerase chain reaction using the COBAS AmpliPrep/COBAS TaqMan (Roche Diagnostics, Mannheim, Germany), and the lower detection limit was 15 IU/ml. Level of anti-HCV was measured using an Abbott ARCHITECT i2000SR. HCV genotype performed using multicolor fluorescence PCR with an HCV RNA genotype kit (BioAssay Science & Technology Co. Ltd., China).

HCV viral load, HCV genotype, serum FBG, fasting insulin levels (FINS) and fasting C peptide (FCP) were collected respectively at baseline, at the end of treatment and at week 24 post-treatment. Three parameters of glucose metabolism, including homeostasis model assessment of insulin resistance (HOMA-IR), homeostasis model assessment- β (HOMA-β) and insulin sensitivity index (ISI), were evaluated by the homeostasis model assessment and were calculated as follows:

HOMA-IR = FINS (μU/ml) × FBG (mmol/l)/22.5.

HOMA-β = 20 × FINS (μU/ml)/(FBG (mmol/l)-3.5).

ISI = ln 1/FINS (μU/ml) × FBG (mmol/l).

Statistical analysis

Continuous variables were presented as means ± SD or median (inter-quartile range), while categorical variables were expressed as frequencies (%). Continuous variables between groups were analyzed using a Student t-test or Mann–Whitney U test while categorical variables were analyzed using a chi-squared test. HCV RNA levels were expressed as the mean ± standard deviation after logarithmic transformation of original values. Multivariate logistic regression was performed as appropriate. The procedures were performed using the SPSS 18.0 statistical package. All statistical analyses were based on two side hypothesis tests, with values P < 0.05 considered to indicate statistical significance.

Results

Demographic and clinical characteristics of the HCV-infected patients and the healthy control group

Demographic and clinical characteristics of the HCV-infected patients and the healthy control groups were presented in Table 1. There was no significant difference in age, gender and BMI between two groups (P = 0.143; P = 0.129 and P = 0.247, respectively). HCV-infected group had a significantly higher baseline fasting blood glucose levels than healthy control (5.57 ± 0.74 vs. 5.11 ± 0.83, P < 0.001). AST, ALT, ALP and GGT levels were also significantly higher in HCV group (P < 0.001 for all).
Table 1

Baseline characteristics of chronic hepatitis C patients and controls

Characteristic

HCV

Control

P value

N

306

325

 

Male (%)

191 (62.4)

179 (55.1)

0.129

Mean age (years)

46.34 ± 5.42

45.97 ± 6.22

0.143

BMI

23.27 ± 3.14

23.53 ± 2.59

0.247

FBG (mmol/l)

5.57 ± 0.74

5.11 ± 0.83

< 0.001

ALT (U/L)

50.4 (29.8–80.35)

27.4 (18.7–42.65)

< 0.001

AST (U/L)

38.0 (27.65–62.8)

24.85 (19.8–33.8)

< 0.001

ALP (U/L)

79.0 (64.0–95.0)

77.0 (63.0–93.0)

< 0.001

GGT (U/L)

40.0 (23.0–96.0)

24.5 (16.0–47.45)

< 0.001

Data are expressed as mean ± SD, median (interquartile range) or as number of patients

BMI body mass index, FBG fasting blood glucose, ALT alanine transaminase, AST aspartate transaminase, ALP alkaline phosphatase, GGT gamma-glutamy ltranspeptidase

Baseline characteristics of SVR and non-SVR patients

Baseline characteristics of 183 HCV-infected patients are presented in Table 2. SVR was obtained in 59.6% (n = 109), and non-SVR in 40.4% (n = 74) of the 183 patients. There was no significant difference in gender and BMI between the two groups. Most HCV genotypes of the patients were 1b or 2a, except 3 patients whose HCV genotypes were not determined. Significant difference was observed in age, genotype, HCV load, ALT and AST levels between SVR and non-SVR groups. The predictors of SVR were young age (P = 0.008), non-genotype 1 (P < 0.001), low HCV load (P < 0.001), high ALT (P = 0.038) and AST levels (P = 0.033) with univariate analysis. However, baseline FBG, INS and HOMA-IR negatively affected treatment response (P = 0.159, 0.534, 0.314).
Table 2

Baseline Characteristics of the Treated HCV Group

 

SVR

non-SVR

P value

N

109

74

 

Male(%)

79 (72.5%)

51 (68.9%)

0.622

Mean age (years)

48.4 ± 7.82

51.8 ± 7.41

0.008

BMI

23.7 ± 2.72

23.7 ± 3.02

0.798

HCV load (Log10)

5.64 ± 1.01

6.35 ± 0.76

< 0.001

HCV genotype (%)

 1b

50 (45.9%)

61 (82.4%)

< 0.001

 2a

56 (51.4%)

13 (17.6%)

 Unclassified

3 (2.7%)

FBG (mmol/l)

5.14 ± 0.81

5.52 ± 0.83

0.159

FCP (nmol/l)

0.92 ± 0.25

0.95 ± 0.33

0.409

FINS (μU/ml)

8.30 ± 3.80

9.08 ± 4.88

0.534

HOMA-IR

2.00 ± 1.02

2.27 ± 1.37

0.314

HOMA-β

104.5 ± 71.92

104.5 ± 77.53

0.9

ISI

−3.70 ± 0.45

−3.77 ± 0.56

0.353

ALT (U/L)

64.0 (34.3, 131.5)

49.6 (30.7, 72.6)

0.038

AST (U/L)

49.4 (32.2, 75.5)

39.9 (30.5, 62.6)

0.033

ALP (U/L)

85.0 (70.5, 113.5)

86.0 (64.8, 106.5)

0.642

GGT (U/L)

45.0 (25.3, 90.8)

44.0 (23.3, 86.3)

0.731

ALB (g/l)

48.2 (44.7, 52.5)

46.9 (43.9, 50.0)

0.064

TBIL (μmol/l)

17.8 (12.9, 28.2)

15.9 (11.3, 23.0)

0.529

CHE (U/L)

7598 (6721, 8030)

7835 (6870, 8148)

0.09

Data are expressed as mean ± SD, median (interquartile range) or as number of patients

BMI body mass index, TC total cholesterol, TG triglyceride, FBG fasting blood glucose, FCP fasting C peptide, FINS fasting insulin, HOMA-IR homeostasis model assessment for insulin resistance, HOMA-β Homeostasis model assessment for beta-cell function, ISI insulin sensitivity index, ALT alanine transaminase, AST aspartate transaminase, ALP alkaline phosphatase, GGT gamma-glutamyltransferase, ALB albumin, TBIL total bilirubin, CHE cholinesterase

Multiple regression analysis found that old age (P = 0.004, OR = 1.072,95% CI: 1.023, 1.123), high viral load (P < 0.001, OR = 2.316, 95% CI: 1.596, 3.362) and genotype 1b (P < 0.001, OR = 2.016, 95% CI: 1.116, 3.122) were predictive of a poor virological response.

Changes in insulin resistance and beta-cell function after antiviral therapy in SVR and non-SVR group

To investigate the effects of HCV clearance on glucose metabolism, we compared some of the metabolic indices of SVR and non-SVR group. Changes in insulin resistance and beta-cell function after antiviral therapy in SVR and non-SVR patients are summarized in Tables 3 and 4. In SVR group, serum FBG, FINS and FCP levels significantly decreased after the end of treatment (from 5.41 ± 0.8 to 4.60 ± 0.68 mmol/l, P < 0.001; from 8.30 ± 3.80 to 7.88 ± 4.15 μU/ml, P = 0.007; from 0.92 ± 0.25 to 0.72 ± 0.26 nmol/l, P < 0.001, respectively). HOMA-IR values also decreased at the end of treatment (from 2.00 ± 1.02 to 1.62 ± 0.94, P < 0.001), and rebounded to 1.86 ± 1.20 at 24 weeks after treatment. Correspondingly, ISI values increased from − 3.70 ± 0.45 at baseline to − 3.45 ± 0.54 (Table 3). However, no significant changes in both parameters of glucose metabolism and HOMA-IR values were observed in non-SVR group (Table 4).
Table 3

Time course of changes in serum beta-cell function during antiviral treatment of patients with SVR

 

Baseline

End-Rx

FU-24

P1 value

P2 value

FBG (mmol/l)

5.41 ± 0.81

4.60 ± 0.68

5.09 ± 0.83

< 0.001

0.002

FINS (μU /ml)

8.30 ± 3.80

7.88 ± 4.15

8.18 ± 3.99

0.007

0.806

FCP (nmol/l)

0.92 ± 0.25

0.72 ± 0.26

0.78 ± 0.27

< 0.001

0.000

HOMA-IR

2.00 ± 1.02

1.62 ± 0.94

1.86 ± 1.20

< 0.001

0.052

HOMA-β

104.5 ± 71.9

183.7 ± 127.8

134.3 ± 108.6

< 0.001

0.01

ISI

−3.70 ± 0.45

−3.45 ± 0.54

−3.60 ± 0.52

< 0.001

0.05

Data are expressed as mean ± SD;

FBG fasting blood glucose, FINS fasting insulin, FCP fasting C peptide, HOMA-IR homeostasis model assessment for insulin resistance, HOMA-β homeostasis model assessment for beta-cell function, ISI insulin sensitivity index, Rx treatment; FU-24, follow up at 24 weeks post treatment

P1, value for comparison of baseline and end-Rx values; P2, value for comparison of baseline and FU-24 values

Table 4

Time course of changes in serum beta-cell function during antiviral treatment of patients non- SVR

 

Baseline

End-Rx

FU-24

P1 value

P2 value

FBG (mmol/l)

5.52 ± 0.83

4.93 ± 0.93

5.23 ± 0.74

< 0.001

0.023

FINS (μU/ml)

9.08 ± 4.88

9.05 ± 5.07

9.58 ± 5.12

0.546

0.888

FCP (nmol/l)

0.95 ± 0.33

0.97 ± 0.29

0.93 ± 0.31

0.609

0.819

HOMA-IR

2.27 ± 1.37

2.16 ± 1.42

2.49 ± 1.37

0.281

0.195

HOMA-β

104.5 ± 77.5

178.7 ± 148.3

144.3 ± 102.9

< 0.001

0.08

ISI

−3.77 ± 0.56

−3.69 ± 0.63

−3.87 ± 0.59

0.250

0.264

Data are expressed as mean ± SD;

FBG fasting blood glucose, FINS fasting insulin, FCP fasting C peptide, HOMA-IR homeostasis model assessment for insulin resistance, HOMA-β homeostasis model assessment for beta-cell function, ISI insulin sensitivity index, Rx treatment; FU-24, follow up at week 24 post treatment

P1, value for comparison of baseline and end-Rx values; P2, value for comparison of baseline and FU-24 values

HOMA-β values in both groups were obviously increased at the end of treatment compared with baseline (P < 0.001 for both). The values decreased slightly at 24 week after end of treatment, but were still higher than pre-treatment levels (P = 0.01 and P = 0.08, respectively).

Discussion

In the present study, we evaluated the association of HCV infection and glucose metabolism; the effect of antiviral treatment on glucose metabolism was also studied [13].

Our results showed that the level of FBG in HCV group was higher than that in control group, which was consistent with other studies. Previous studies has revealed that HCV infection causes insulin resistance and glucose abnormalities even type 2 diabetes mellitus (T2DM) in susceptible individuals [11, 14]. Another long period follow-up study showed the cumulative incidence of T2DM in anti-HCV positive patients reached 14.3% while only 8.6% in seronegative individuals (P < 0.0001) [15].

The relation between IR and SVR are controversy. Our study revealed that many factors at baseline such as age, HCV genotype, HCV load, ALT and AST levels were able to predict SVR, but there was no significant association between FBG, INS, HOMA-IR with SVR. A meta-analysis for the association between insulin resistance and SVR in hepatitis-C infected patients indicated that there was no relation between them and the mean value of HOMA-IR was less than 3 at baseline in all studies [16]. Other studies reported that pretreatment glucose intolerance and IR could impair the therapy outcome [17, 18]. The association of IR and SVR needs further prospective studies.

Clearance of HCV infection may improve IR and increase insulin sensitivity. In our study, we found that in SVR patients eradication of HCV by interferon-based therapy could improve insulin resistant and decreased fasting insulin as well as C peptide levels, whereas no significant difference in these indices was found in non-SVR patient. This result suggested that HCV itself might be involved in the development of insulin resistance. The mechanisms that HCV induces glucose metabolism abnormities are not very clear.

Several different mechanisms may be involved. HCV-induced liver inflammation and cirrhosis may reduce the uptake of glucose by hepatic cells, then affect the glucose metabolism [19]; HCV infection may also impair IRS-1 tyrosine phosphorylation. As anessential molecule in insulin signaling, the dysfunction of IRS-1 could decrease downstream insulin effects, thereby contributing to glucose intolerance. Clearance of HCV results in a significant increase of IRS-1 expression, which may partly restore glucose metabolism [7, 20]. In addition, HCV core proteins may functionally inhibit insulin signaling via increasing the level of tumor necrosis factor-alpha (TNF-α), which is an important factor mediating insulin signaling [21]. HCV core proteins also down regulate the cell surface expression of glucose transporter 2 (GLUT2), promoting hepatic gluconeogenesis via suppression of glucose uptake [19, 22]. Finally, some proinflammatory cytokines such as IL-6 and TGF-β also have been identified to be able to reduce glucose uptake and impair glucagon metabolism in HCV infected patients.

Our study also showed that HOMA-β was significantly increased after antiviral treatment regardless of the outcome. The mechanism may be attribute to the restoration of insulin sensitivity after the clearance of HCV [23]. The current data confirmed that HOMA-β values increased in the CHC patients as compensation for insulin resistance [24, 25], and at the same time the status of beta-cell hyperfunction was ameliorated after successful treatment [26]. The mechanisms that whether or not HCV could change the function of beta-cell in chronic hepatitis C patients remains unclear. Early studies reported that virus-like particles were detected in the pancreatic beta cells of HCV patients, which could induce death of pancreatic beta cells through multiple mechanisms [27, 28]. While many clinical studies reported that beta-cell function was preserved [29].

Larger amount of samples was included in our study than other studies [2, 14], which increased the statistical reliability of the results. Although the therapy agents in the study were no longer generally used for the treatment of HCV, the interferon and ribavirin combination therapy still plays an important role in certain limited resource settings. There were also certain limitations. The current study was retrospective, and some data missed in some cases. However, we proposed that no matter what kind of antiviral treatment was used, clearance of HCV could improve insulin resistant and decrease fasting glucose [11, 20]. It is still interesting to study the impact of conventional methods on metabolic endpoints.

Conclusions

The current study showed that chronic HCV-infected patients had higher fasting blood glucose levels than healthy controls. Successful clearance of HCV by interferon-based therapy led to reversal of hyperglycemia and improvement of insulin resistance However, the effect of HCV infection on beta cell function is complex and further studies are required to clarify their association.

Notes

Acknowledgements

The authors want to claim that the work has been presented as a poster presentation at 66th American Association for the Study of Liver Diseases (AASLD), San Francisco, USA, 2015.

Authors’ contributions

All contributing authors have agreed to the submission of this manuscript for publication. YL, XW and JN designed and were major contributors in writing the manuscript. GY, HS, and JL acquired data. XC, RW and XG performed the examination of the FBG and other tests. All authors have read and approved the final version of this manuscript.

Funding

The study was sponsored by the National Basic Research Program of China (973 Program) (2015CB554300), the National Natural Science Foundation of China (grants No.81301472).

Ethics approval and consent to participate

The study protocol was approved by the ethics committee of the First Hospital of Jilin University. Written informed consent for all testing was obtained prior to enrollment.

Consent for publication

Not applicable. No details, images, or videos relating to individual participants are included in the manuscript.

Competing interests

All authors declare no conflict of interest.

References

  1. 1.
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41–52.CrossRefGoogle Scholar
  2. 2.
    Qing S, Ji D, Li B, Li F, Wang Y, Niu X, Ling B, Meng Y, Lau G, Chen G. Improvement of glucose and lipid metabolism with pegylated interferon-a plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus. Ann Saudi Med. 2015;35(4):293–7.CrossRefGoogle Scholar
  3. 3.
    Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, Yamamoto AM, Camproux AC, Hausfater P, Musset L, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine interne et maladies Infectieuses Sur le virus de l'Hepatite C. Medicine (Baltimore). 2000;79(1):47–56.CrossRefGoogle Scholar
  4. 4.
    Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(Suppl 5):S165–73.CrossRefGoogle Scholar
  5. 5.
    Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A, Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol. 2004;41(1):132–8.CrossRefGoogle Scholar
  6. 6.
    Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134(2):416–23.CrossRefGoogle Scholar
  7. 7.
    Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38(6):1384–92.CrossRefGoogle Scholar
  8. 8.
    Taskoparan M, Serin E, Gokturk HS, Icer MO, Abaci K, Ozer B, Zumrutdal A, Yilmaz U. Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C. Hepatogastroenterology. 2011;58(107–108):875–9.PubMedGoogle Scholar
  9. 9.
    Tada S, Saito H, Ebinuma H, Ojiro K, Yamagishi Y, Kumagai N, Inagaki Y, Masuda T, Nishida J, Takahashi M, et al. Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism. Hepatol Res. 2009;39(2):195–9.CrossRefGoogle Scholar
  10. 10.
    Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol. 2001;34(3):428–34.CrossRefGoogle Scholar
  11. 11.
    Adinolfi LE, Nevola R, Guerrera B, D'Alterio G, Marrone A, Giordano M, Rinaldi L. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33(7):1379–82.CrossRefGoogle Scholar
  12. 12.
    Cheng YL, Wang YC, Lan KH, Huo TI, Huang YH, Su CW, Lin HC, Lee FY, Wu JC, Lee SD. Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. Ann Hepatol. 2015;14(2):181–9.CrossRefGoogle Scholar
  13. 13.
    Yinping Li XW, Hongqin X, Ruihong W, Chi X, Gao X, Pan Y, Niu J. The influence of hepatitis C virus infection and its clearance on the serum lipid profile and glucose leve. American Association for the Study of Liver Diseases (AASLD). 2015.Google Scholar
  14. 14.
    Yair-Sabag S, Nussinson E, Ben-Assuli O, Shibli F, Shahbari A, Zelber-Sagi S. Retrospective study of the associations between hepatitis C virus infection and metabolic factors. World J Hepatol. 2016;8(30):1269–78.CrossRefGoogle Scholar
  15. 15.
    Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol. 2007;166(2):196–203.CrossRefGoogle Scholar
  16. 16.
    Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 2011;34(3):297–305.CrossRefGoogle Scholar
  17. 17.
    Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128(3):636–41.CrossRefGoogle Scholar
  18. 18.
    Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, George J. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol. 2008;48(1):28–34.CrossRefGoogle Scholar
  19. 19.
    Kralj D, Virovic Jukic L, Stojsavljevic S, Duvnjak M, Smolic M, Curcic IB. Hepatitis C virus, insulin resistance, and steatosis. J Clin Transl Hepatol. 2016;4(1):66–75.CrossRefGoogle Scholar
  20. 20.
    Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570–6.CrossRefGoogle Scholar
  21. 21.
    Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol. 2003;98(12):2751–6.PubMedGoogle Scholar
  22. 22.
    Shoji I, Deng L, Matsui C, Hotta H. Hepatitis C virus-induced glucose metabolic disorder. Uirusu. 2015;65(2):263–8.CrossRefGoogle Scholar
  23. 23.
    Carvalho JR, Velosa J, Serejo F. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens. Scand J Gastroenterol. 2018:1–7.Google Scholar
  24. 24.
    Kawaguchi Y, Mizuta T, Oza N, Takahashi H, Ario K, Yoshimura T, Eguchi Y, Ozaki I, Hisatomi A, Fujimoto K. Eradication of hepatitis C virus by interferon improves whole-body insulin resistance and hyperinsulinaemia in patients with chronic hepatitis C. Liver Int. 2009;29(6):871–7.CrossRefGoogle Scholar
  25. 25.
    Furutani M, Nakashima T, Sumida Y, Hirohama A, Yoh T, Kakisaka Y, Mitsuyoshi H, Senmaru H, Okanoue T. Insulin resistance/beta-cell function and serum ferritin level in non-diabetic patients with hepatitis C virus infection. Liver Int. 2003;23(4):294–9.CrossRefGoogle Scholar
  26. 26.
    Huang JF, Dai CY, Yu ML, Huang CF, Huang CI, Yeh ML, Yang JF, Hou NJ, Hsiao PJ, Lin ZY, et al. Pegylated interferon plus ribavirin therapy improves pancreatic beta-cell function in chronic hepatitis C patients. Liver Int. 2011;31(8):1155–62.CrossRefGoogle Scholar
  27. 27.
    Wang Q, Chen J, Wang Y, Han X, Chen X. Hepatitis C virus induced a novel apoptosis-like death of pancreatic beta cells through a caspase 3-dependent pathway. PLoS One. 2012;7(6):e38522.CrossRefGoogle Scholar
  28. 28.
    Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, Lupi R, Del Guerra S, Bugliani M, Torri S, et al. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care. 2005;28(4):940–1.CrossRefGoogle Scholar
  29. 29.
    Lecube A, Hernandez C, Genesca J, Simo R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care. 2006;29(5):1096–101.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Yinping Li
    • 1
    • 2
  • Xiaomei Wang
    • 1
    • 3
  • Ge Yu
    • 1
  • Haibo Sun
    • 1
  • Juan Lv
    • 1
  • Xiumei Chi
    • 1
    • 3
  • Ruihong Wu
    • 1
    • 3
  • Xiuzhu Gao
    • 1
    • 3
  • Junqi Niu
    • 1
    • 3
    Email author
  1. 1.Department of Hepatologythe First hospital of Jilin UniversityChangchunChina
  2. 2.Department of GastroenterologyShouguang City People’s HospitalShouguangChina
  3. 3.Key Laboratory of Zoonosis Research, Ministry EducationChangchunChina

Personalised recommendations